Ten post jest także dostępny w języku: polski
On 18 February Marek Dziki resigned from the position of Member of the Management Board of Bioton. The resignation has immediate effect. It is due to personal reasons.
Marek Dziki has been a Member of the Management Board of Bioton since February 2016. At the same time, he is the CEO and Chairman of the Supervisory Board of SciGen Ltd. (this company previously belonged to Bioton). He is also the Chairman of the Supervisory Board in the Italian company Pharmatex and a member of the Management Board of another Italian company Fisiopharma. He is also the Chairman of M&M Pharma and a consultant with the Swiss company Lumeden.
Bioton is a Polish pharmaceutical company. Its leading product is Gensulin, which in the third quarter of 2018 was the leader of the classical insulin market in Poland. Its share exceeded 34%. In total, in the first three quarters of 2018, insulin sales accounted for over 60% of the company’s revenues.